Skip to content

Study · Animal study (in vivo) · rat · 1992

3 results

Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.

Reissmann T, Hilgard P, Harleman JH, Engel J, Comaru-Schally AM, Schally AV

Journal of cancer research and clinical oncology1 Jan 1992Cited by 14 (Europe PMC)

PMID1530849 (opens in a new tab)PMCIDPMC12200549 (opens in a new tab)DOI10.1007/bf01192310 (opens in a new tab)PepBankPUB-01530849
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with recurrent DMBA-induced tumors after Cetrorelix withdrawal, subsequent Decapeptyl treatment produced tumor regression within 10 days.

    In plain wordsIn rats with recurrent tumors after Cetrorelix withdrawal, subsequent Decapeptyl treatment produced tumor regression within 10 days.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseTumor regression after sequential Decapeptyl
    Study

    ratn: not reported in source

    DMBA-induced mammary carcinoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    50 micrograms/rat/day · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    Again, the tumors responded well and regressed within 10 days.
    1 context sentence
    Summary · context
    After the cessation of treatment with 100 micrograms/kg/d and regrowth of the tumors the animals were treated with the agonist Decapeptyl (Trp6-LHRH) using a dose of 50 micrograms/rat/d for 14 days.

Studies that did not test the peptide alone2

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 02AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Efficacy outcome

    In rats with DMBA-induced mammary tumors, overlapping Cetrorelix and Decapeptyl treatment produced a continuous antitumor response.

    In plain wordsIn rats with mammary tumors, overlapping Cetrorelix and Decapeptyl treatment produced a continuous antitumor response.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseContinuous antitumor response with overlapping regimen
    Study

    ratn: not reported in source

    DMBA-induced mammary carcinoma
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The treatment with an overlapping dose schedule of Cetrorelix and Decapeptyl showed a continuous antitumor response.
    1 context sentence
    Summary · context
    After the cessation of treatment with 100 micrograms/kg/d and regrowth of the tumors the animals were treated with the agonist Decapeptyl (Trp6-LHRH) using a dose of 50 micrograms/rat/d for 14 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 03AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Safety outcome

    In rats with DMBA-induced mammary tumors, no transient agonist-associated tumor growth stimulation occurred under the Cetrorelix and Decapeptyl treatment conditions.

    In plain wordsIn rats with mammary tumors, no transient agonist-associated tumor growth stimulation occurred under the Cetrorelix and Decapeptyl treatment conditions.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeTransient tumor growth stimulation
    Study

    ratn: not reported in source

    DMBA-induced mammary carcinoma
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    A transient stimulation of tumor growth by the LH-RH agonist was not observed under these experimental conditions.
    2 context sentences
    Summary · context
    The treatment with an overlapping dose schedule of Cetrorelix and Decapeptyl showed a continuous antitumor response.
    Summary · context
    After the cessation of treatment with 100 micrograms/kg/d and regrowth of the tumors the animals were treated with the agonist Decapeptyl (Trp6-LHRH) using a dose of 50 micrograms/rat/d for 14 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.